Among the FDA-approved medications for addiction treatment, Vivitrol — the brand name for extended-release naltrexone — occupies a distinct and important place. Unlike buprenorphine (Suboxone) or methadone, which are opioid agonists that work by activating opioid receptors, Vivitrol is an opioid antagonist: it blocks opioid receptors. It’s also different from other forms of naltrexone in that it’s given as a once-monthly injection, removing the daily adherence challenge of an oral pill.
Vivitrol is approved for both opioid use disorder and alcohol use disorder, and it has meaningful advantages for certain patients — particularly those who have completed opioid detox and prefer a non-opioid, non-daily approach. This article explains how Vivitrol differs from Suboxone, its mechanism of action, who’s a good candidate, why detox is required before starting it, and practical considerations. All prescribing and medical decisions belong entirely to qualified medical professionals.
—
HOW VIVITROL DIFFERS FROM SUBOXONE
Because both Vivitrol and Suboxone (buprenorphine/naloxone) are commonly discussed in the context of opioid use disorder treatment, understanding their fundamental differences helps patients have informed conversations with their providers.
| Feature | Vivitrol (naltrexone injection) | Suboxone (buprenorphine/naloxone) |
| Drug class | Opioid antagonist (blocker) | Partial opioid agonist + antagonist |
| How it works | Blocks opioid receptors completely | Partially activates opioid receptors |
| Effect if opioids taken | No euphoria; opioids have little/no effect | Opioid effect reduced; ceiling on effect |
| Dosing schedule | Once monthly injection | Daily sublingual film or tablet |
| Detox required first | Yes — must be opioid-free before starting | No — can begin during withdrawal |
| Addresses withdrawal | Does not manage active withdrawal | Actively manages withdrawal |
| Physical dependence | None | Yes, body adapts to buprenorphine |
| Good for alcohol? | Yes — FDA-approved for AUD | Not typically used for AUD |
The key summary: Suboxone is itself an opioid medication that manages withdrawal and craving through partial receptor activation, while Vivitrol is a non-opioid blocker that works after detox is complete. Both are evidence-based; they work differently and suit different patients.
—
MECHANISM OF ACTION
Understanding how Vivitrol (naltrexone) works helps explain both its benefits and its requirements.
Naltrexone is an opioid antagonist — it binds to opioid receptors with high affinity but does not activate them. Instead, it occupies the receptors and blocks them, preventing opioids from binding and producing their effects. If someone on Vivitrol uses an opioid, the opioid cannot bind effectively to the blocked receptors, so the expected euphoria and reward effects are greatly diminished or eliminated.
For opioid use disorder, this mechanism:
- Removes the reward from opioid use. Since using an opioid while on Vivitrol produces little or no euphoric effect, the reinforcing reason to use is blocked.
- Reduces cravings over time. By disrupting the opioid reward cycle consistently, Vivitrol can help reduce cravings.
For alcohol use disorder, naltrexone works somewhat differently but through related mechanisms:
- Reduces the rewarding effects of alcohol. Alcohol’s pleasurable effects involve the endorphin/opioid system in the brain; by blocking opioid receptors, naltrexone blunts the reward alcohol provides, reducing the urge to drink.
- Clinical evidence supports its effectiveness for both reducing heavy drinking days and supporting abstinence.
The extended-release injection (Vivitrol) provides steady naltrexone levels for approximately one month, which is a key advantage: it eliminates the daily adherence challenge of taking an oral pill, and it means that even if a person has a craving or impulse moment, the medication is already in effect. They can’t “skip today’s dose” in anticipation of using.
—
WHO’S A GOOD CANDIDATE
Vivitrol is not the right medication for every patient, and the determination of candidacy is entirely a clinical decision. However, some general patterns characterize patients for whom Vivitrol may be particularly well-suited, which can inform the conversation with a provider.
Generally good candidates may include:
- People who have completed medically supervised opioid detox and are fully opioid-free. This is a non-negotiable medical requirement (detailed below), not a preference.
- People who prefer a non-opioid approach to medication. Some patients are strongly motivated to use a medication that does not itself act on opioid receptors; Vivitrol is the only currently available long-term opioid treatment that is not an opioid agonist.
- People for whom adherence to a daily oral medication is a challenge. The once-monthly injection eliminates daily pills.
- People with alcohol use disorder who might also benefit from an opioid treatment medication (Vivitrol is the only MAT approved for both).
- People returning to high-risk environments who want the protection of a medication they can’t easily stop on impulse.
- People with opioid use disorder in settings where daily clinic visits (methadone) or daily medication management (Suboxone) are impractical.
- Motivated, stable patients who have support systems and are engaged in therapy.
Patients who are generally not good candidates (again, clinical decision):
- Anyone who is not fully opioid-free and detoxified. Starting Vivitrol before completing detox can precipitate severe, sudden opioid withdrawal — a serious medical risk.
- Those with certain liver conditions, as naltrexone is processed by the liver and requires liver function monitoring.
- Those who still need active withdrawal management, for whom agonist medications may be more appropriate initially.
—
DETOX REQUIRED BEFORE STARTING
One of the most critical medical facts about Vivitrol is that opioid detox must be completed before starting it. This is not optional, and attempting to start Vivitrol before the body has cleared opioids can precipitate withdrawal — a sudden, severe onset of withdrawal symptoms that is medically dangerous and extremely distressing.
Why this happens: Vivitrol (naltrexone) is an opioid antagonist that immediately blocks and displaces opioids from receptors. If opioids are still present in the system, this sudden displacement triggers intense, sudden withdrawal. It is a serious medical complication to be avoided by ensuring complete detox before initiation.
What “fully detoxified” means: The specific window of opioid-free time required before safely starting Vivitrol depends on the type of opioid (short-acting vs. long-acting, including buprenorphine, which requires a longer opioid-free period) and is determined by the medical team. A challenge dose of oral naloxone may be used to confirm readiness before initiating the injection.
This requirement is exactly why medically supervised detox — in a setting like Oceánica’s residential program — is such a natural bridge to Vivitrol: the medically supervised detox completes the necessary opioid clearance under medical care, after which Vivitrol can be considered as part of the continuing care and aftercare plan, with all timing and decisions made by the medical team.
—
COST & INSURANCE
Practical considerations around cost and coverage are real factors for many patients.
Cost:
- Vivitrol is a branded medication and can be expensive without insurance coverage. The manufacturer has patient assistance programs for those who qualify.
- Oral naltrexone (generic) is substantially less expensive than Vivitrol and provides the same pharmacological action, though without the adherence advantage of the monthly injection. Providers may consider this as an alternative for cost-sensitive patients.
Insurance:
- Many U.S. insurance plans, including Medicaid and Medicare, cover Vivitrol, though coverage varies by plan and state.
- Coverage verification requires contacting the insurance plan directly.
- The manufacturer’s patient assistance program can help those without adequate coverage.
For patients treating at Oceánica (which does not bill U.S. insurance directly) and transitioning back to the U.S., connecting with a U.S.-based prescriber and verifying insurance coverage for Vivitrol are practical steps that can be planned during aftercare preparation. The Oceánica team can help connect patients with appropriate aftercare resources in their home community.
—
FREQUENTLY ASKED QUESTIONS
- What is Vivitrol and how does it work?
Vivitrol is the brand name for extended-release naltrexone, given as a once-monthly injection. It works as an opioid antagonist — it blocks opioid receptors so that opioids produce little or no euphoric effect if used, removing the reward of using. For alcohol use disorder, it blunts the rewarding effects of alcohol, reducing cravings and drinking.
- Why must I detox completely before starting Vivitrol?
Because naltrexone is an opioid blocker, starting it while opioids are still present in the system can immediately displace opioids from receptors and trigger severe, sudden withdrawal (precipitated withdrawal). All opioids must be cleared first, over a medically supervised period; the timing is determined by the medical team.
- How is Vivitrol different from Suboxone?
Vivitrol is a non-opioid blocker; Suboxone is a partial opioid agonist. Suboxone can be started during active withdrawal, manages withdrawal directly, and is taken daily. Vivitrol requires completed detox first, doesn’t manage active withdrawal, and is given as a monthly injection. Both are evidence-based; the right choice is a clinical decision.
- Is Vivitrol effective for alcohol as well as opioids?
Yes. Vivitrol is FDA-approved for both opioid use disorder and alcohol use disorder, and naltrexone has substantial evidence supporting its effectiveness for alcohol use disorder, reducing heavy drinking days and supporting abstinence.
—
SUGGESTED INTERNAL LINKS
Medication-Assisted Treatment (MAT): Evidence Over Stigma
Naltrexone for Alcohol Use Disorder
Opioid Addiction Treatment in Mexico
Services and Programs at Oceánica
EXTERNAL REFERENCE LINKS
- Oceánica conecta
- SAMHSA — Naltrexone
- FDA — Vivitrol (naltrexone)
- NIDA — Medications to Treat Opioid Use Disorder
—
Oceánica is a CARF-accredited residential treatment center in Mazatlán, Mexico, where opioid and alcohol use disorders are treated with comprehensive, individualized care — with all medication decisions, including any regarding naltrexone, made by qualified medical staff. This article is informational and not medical advice. Call (213) 527-3377 or visit oceanica-usa.com.
